We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

Pfizer (PFE) CEO Albert Bourla said he's learned to work with some unlikely allies — even those who once questioned the very foundation of his business. "Clearly, that was not going to be my choice ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...

Pfizer CEO Albert Bourla says the company is looking for "superior" results on weight-loss drugs. Speaking with Katie ...

Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...

Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with ...